The evolving landscape of neuroendocrine tumors

Seminars in Oncology

Volumn 40, Issue 1, 2013, Pages 4-22

  Bergsland, Emily K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AXITINIB; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CIXUTUMUMAB; DOXAZOSIN; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR; KI 67 ANTIGEN; LUTETIUM 177; MAMMALIAN TARGET OF RAPAMYCIN; MITOTANE; NEUROFIBROMIN; OCTREOTIDE; PASIREOTIDE; PAZOPANIB; PEGINTERFERON; PHENOXYBENZAMINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOSTATIN; STREPTOZOCIN; SUCCINATE DEHYDROGENASE; TEMOZOLOMIDE; VASCULOTROPIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOID; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MOLECULAR MECHANICS; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SYMPTOM; SYSTEMIC THERAPY; THYROID CANCER; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; CLINICAL TRIALS AS TOPIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; SOMATOSTATIN;

EID: 84873362957     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.11.013     Document Type: Article

References (131)

1. S.N. Hochwald, S. Zee, K.C. Conlon Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups J Clin Oncol 20 2002 2633 2642
2. th ed. 2010 Springer New York
3. D.S. Klimstra, I.R. Modlin, D. Coppola The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems Pancreas 39 2010 707 712
4. G. Rindi, R. Arnold, F. Bosman Nomenclature and classification of neuroendocrine neoplasms of the digestive system 2010 IARC Press Lyon
5. G. Rindi, G. Kloppel, A. Couvelard TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system Virchows Arch 451 2007 757 762
6. G. Rindi, G. Kloppel, H. Alhman TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system Virchows Arch 449 2006 395 401
7. J. Shia, L.H. Tang, M.R. Weiser Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 32 2008 719 731
8. M. Jamali, R. Chetty Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining Endocr Pathol 19 2008 282 288
9. E. Vilar, R. Salazar, J. Perez-Garcia Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors Endocr Rel Cancer 14 2007 221 232
10. U. Plockinger, G. Rindi, R. Arnold Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) Neuroendocrinology 80 2004 394 424
11. H. Sorbye, S. Welin, S.W. Langer Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study Ann Oncol 24 2013 152 160
12. Z. Yang, L.H. Tang, D.S. Klimstra Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification Am J Surg Pathol 35 2011 853 860
13. Z. Yang, L. Tang, D. Klimstra How many needle core biopsies are needed to comfortably predict the histologic grade of metastatic well differentiated neuroendocrine tumors to the liver? Mod Pathol 25 2012 426A
14. O. Lin, S. Olgac, I. Green Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms Am J Clin Pathol 120 2003 209 216
15. G. Kloppel, G. Rindi, A. Perren The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement Virchows Arch 456 2010 595 597
16. A. Dolcetta-Capuzzo, V. Villa, L. Albarello Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models Cancer 119 2013 36 44
17. G. Capurso, S. Festa, R. Valente Molecular pathology and genetics of pancreatic endocrine tumors J Mol Endocrinol 49 2012 R37 R50
18. F. Raue, K. Frank-Raue Update multiple endocrine neoplasia type 2 Fam Cancer 9 2010 449 457
19. S.K. Agarwal, S.C. Guru, C. Heppner Menin interacts with the AP1 transcription factor JunD and represses JunD-Activated transcription Cell 96 1999 143 152
20. P. Durbec, C.V. Marcos-Gutierrez, C. Kilkenny GDNF signalling through the Ret receptor tyrosine kinase Nature 381 1996 789 793
21. V. Besset, R.P. Scott, C.F. Ibanez Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase J Biol Chem 275 2000 39159 39166
22. C. Eng, D. Clayton, I. Schuffenecker The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 International RET mutation consortium analysis JAMA 276 1996 1575 1579
23. G. Randolph, D. Maniar Medullary carcinoma of the thyroid Cancer Control 7 2000 252 261
24. D. Marsh, D. Learoyd, S. Andrew Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma Clin Endocrinol (Oxf) 44 1996 249 257
25. A. Gimenez-Roqueplo, P. Dahia, M. Robledo An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes Horm Metab Res 44 2012 328 333
26. R.R. Lonser, G.M. Glenn, M. Walther von Hippel-Lindau disease Lancet 361 2003 2059 2067
27. M. Charlesworth, C. Verbeke, G. Falk Pancreatic lesions in von Hippel-Lindau disease? A systematic review and meta-synthesis of the literature J Gastrointest Surgery 16 2012 1422 1428
28. 2 sensing and cancer Nat Rev Cancer 8 2008 865 873
29. Galan S, Kann P. Genetics and molecular pathogenesis of phaeochromocytoma and paraganglioma. Clin Endocrinol (Oxf). Epub ahead of print, 2012.
30. C.M. Johannessen, B.W. Johnson, S.M. Williams TORC1 is essential for NF1-Associated malignancies Curr Biol 18 2008 56 62
31. Y. Jiao, C. Shi, B.H. Edil DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331 2011 1199 1203
32. E. Missiaglia, I. Dalai, S. Barbi Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway J Clin Oncol 28 2010 245 255
33. J. Rutter, D.R. Winge, J.D. Schiffman Succinate dehydrogenase - assembly, regulation and role in human disease Mitochondrion 10 2010 393 401
34. N. Burnichon, J.J. Briere, R. Libe SDHA is a tumor suppressor gene causing paraganglioma Hum Mol Genet 19 2010 3011 3020
35. E. Korpershoek, J. Favier, J. Gaal SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas J Clin Endocrinol Metab 96 2011 E1472 E1476
36. A. Cervera, J. Bayley, P. Devilee Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells Mol Cancer 8 2009 1 7
37. C. Bardella, P. Pollard, I. Tomlinson SDH mutations in cancer Biochim Biophys Acta 1807 2011 1432 1443
38. A.J. Gill, D.E. Benn, A. Chou Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes Hum Pathol 41 2010 805 814
39. H. Kunst, M. Rutten, J. de Monnink SDHAF2 (PGL2-SDH5) and hereditary head and neck paragangliomas Clin Cancer Res 17 2011 247 254
40. M. Sevilla, M. Hermsen, M. Weiss Chromosomal changes in sporadic and familial head and neck paragangliomas Otolaryngol Head Neck Surg 140 2009 724 729
41. V. Ramundo, T. Ercolino, A. Faggiano Genetic-clinical profile of subjects with apparently sporadic extra-Adrenal paragangliomas Front Endocrinol (Lausanne) 3 2012 1 5
42. J.L. Cunningham, T. Diaz de Stahl, T. Sjoblom Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors Genes Chromosomes Cancer 50 2011 82 94
43. M.H. Kulke, E. Freed, D.Y. Chiang High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss Genes Chromosomes Cancer 47 2008 591 603
44. K. Hemminki, X. Li Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden Int J Cancer 94 2001 444 448
45. D. Simon, G. Hammer Adrenocortical stem cells and progenitor cells: implications for adrenocortical carcinoma Mol Cell Endocrinol 351 2012 2 11
46. M. Papotti, M. Bongiovanni, M. Volante Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis Virchows Arch 440 2002 461 475
47. L.K. Kvols, C.G. Moertel, M.J. O'Connell Treatment of the malignant carcinoid syndrome Evaluation of a long-Acting somatostatin analogue N Engl J Med 315 1986 663 666
48. J. Rubin, J. Ajani, W. Schirmer Octreotide acetate long-Acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome J Clin Oncol 17 1999 600 606
49. P. Ruszniewski, M. Ducreux, J.A. Chayvialle Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients Gut 39 1996 279 283
50. M.S. Khan, F. El-Khouly, P. Davies Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel) Aliment Pharmacol Ther 34 2011 235 242
51. C. Toumpanakis, J. Garland, L. Marelli Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR Aliment Pharmacol Ther 30 2009 733 740
52. D. O'Toole, A. Saveanu, A. Couvelard The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies Eur J Endocrinol 155 2006 849 857
53. I.M. Modlin, M. Pavel, M. Kidd Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours Aliment Pharmacol Ther 31 2010 169 188
54. A. Rinke, H.H. Muller, C. Schade-Brittinger Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663
55. L. Kvols, B. Wiedenmann, K. Oberg Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study Pro Am Soc Clin Oncol 2006 171 Chicago; [abstract]
56. J.J. Teunissen, D.J. Kwekkeboom, R. Valkema Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours Endocr Relat Cancer 18 Suppl 1 2011 S27 S51
57. D.J. Kwekkeboom, W.W. de Herder, E.P. Krenning Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors Endocrinol Metab Clin North Am 40 2011 173 185
58. L. Villard, A. Romer, N. Marincek Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers J Clin Oncol 30 2012 1100 1106
59. L. Kolby, G. Persson, S. Franzen Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours Br J Surg 90 2003 687 693
60. R. Arnold, A. Rinke, K.J. Klose Octreotide versus octreotide plus interferon-Alpha in endocrine gastroenteropancreatic tumors: a randomized trial Clin Gastroenterol Hepatol 3 2005 761 771
61. M. Pavel, E. Baudin, A. Couvelard ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary Neuroendocrinology 95 2012 157 176
62. J. Boudreaux, D. Klimstra, M. Hassan The NANETS consensus guidelines for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum Pancreas 39 2010 753 766
63. M.H. Kulke, H.J. Lenz, N.J. Meropol Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 2008 3403 3410
64. A. Phan, J.C. Yao, D.R. Fogleman A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC) Pro Am Soc Clin Oncol 2010 abstract 4001
65. J.C. Yao, A. Phan, P.M. Hoff Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b J Clin Oncol 26 2008 1316 1323
66. M.E. Pavel, J.D. Hainsworth, E. Baudin Everolimus plus octreotide long-Acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
67. M.H. Kulke, L.L. Siu, J.E. Tepper Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting J Clin Oncol 29 2011 934 943
68. J.C. Yao, J.D. Hainsworth, E.M. Wolin Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET) Proc Am Soc Clin Oncol. J Clin Oncol 30 suppl 2012 abstract 4014
69. S. Faivre, C. Delbaldo, K. Vera Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 2006 25 35
70. E. Raymond, L. Dahan, J.L. Raoul Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 501 513
71. A. Vinik, E. Van Cutsem, P. Niccoli Updated results from a phase III trial of sunitinib versus placebo in patients with progressive unresectable, well-differentiated pancreatic neuroendocrine tumor (NET) J Clin Oncol 30 2012 abstract 4118
72. J.C. Yao, M.H. Shah, T. Ito Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
73. P.N. Cheng, L.B. Saltz Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma Cancer 86 1999 944 948
74. A.D. McCollum, M.H. Kulke, D.P. Ryan Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors Am J Clin Oncol 27 2004 485 488
75. M.A. Kouvaraki, J.A. Ajani, P. Hoff Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas J Clin Oncol 22 2004 4762 4771
76. M.H. Kulke, K. Stuart, P.C. Enzinger Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors J Clin Oncol 24 2006 401 406
77. M. Kulke, K. Stuart, C.C. Earle A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors Pro Am Soc Clin Oncol 2006 abstract 4044
78. M.H. Kulke, J.L. Hornick, C. Frauenhoffer O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors Clin Cancer Res 15 2009 338 345
79. J.R. Strosberg, R.L. Fine, J. Choi First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas Cancer 117 2011 268 275
80. M.E. Hegi, A.C. Diserens, T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
81. B. Givi, S.J. Pommier, A.K. Thompson Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival Surgery 140 2006 891 897
82. P.G. Schurr, T. Strate, K. Rese Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience Ann Surg 245 2007 273 281
83. R.S. Chamberlain, D. Canes, K.T. Brown Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190 2000 432 445
84. S.C. Mayo, M.C. de Jong, C. Pulitano Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis Ann Surg Oncol 17 2010 3129 3136
85. S.C. Pitt, J. Knuth, J.M. Keily Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg 12 2008 1951 1960
86. C.Q. Cao, T.D. Yan, L. Bester Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases Br J Surg 97 2010 537 543
87. 90Y- microspheres: early results in 148 patients Am J Clin Oncol 31 2008 271 279
88. S. Sherman Cytotoxic chemotherapy for differentiated thyroid carcinoma Clin Oncol (R Coll Radiol) 22 2010 464 468
89. S. Wells, B. Robinson, R. Gagel Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial J Clin Oncol 30 2012 134 141
90. P. Schoffski, R. Elisei, S. Muller et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantanib (XL184) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline J Clin Oncol 30 2012 abstract 5508
91. M. Schlumberger, R. Elisei, L. Bastholt Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer J Clin Oncol 27 2009 3794 3801
92. A. Sangoi, J. McKenney A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma Am J Surg Pathol 34 2010 423 432
93. M. Enriquez, P. Lal, A. Ziober The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms Appl Immunohistochem Mol Morphol 20 2012 141 145
94. N. Rechache, Y. Wang, H. Stevenson DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors J Clin Endocrinol Metab 97 2012 E1004 E1013
95. S. Hochwald, S. Zee, K. Conlon Prognostic factors in pancreatic endocrine neoplasms: an anlaysis of 136 cases with a proposal for low-grade and intermediate-grade groups J Clin Oncol 20 2002 2633 2642
96. G. Rindi, G. Kloppel, A. Couvelard TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system Vichows Arch 451 2007 757 762
97. C.G. Moertel, L.K. Kvols, M.J. O'Connell Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin Evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 1991 227 232
98. J.R. Strosberg, D. Coppola, D.S. Klimstra The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas Pancreas 39 2010 799 800
99. S. Yachida, E. Vakiani, C.M. White Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors Am J Surg Pathol 36 2012 173 184
100. S. Ryuge, Y. Sato, S. Jiang Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung Lung Cancer 77 2012 415 420
101. S. Welin, H. Sorbye, S. Sebjornsen Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy Cancer 117 2011 4617 4622
102. S. Philips, S.N. Shah, R. Vikram Pancreatic endocrine neoplasms: a current update on genetics and imaging Br J Radiol 85 2012 682 696
103. A.G. Rockall, R.H. Reznek Imaging of neuroendocrine tumours (CT/MR/US) Best practice & research Clin Endocrinol Metab 21 2007 43 68
104. J.L. Fidler, J.G. Fletcher, C.C. Reading Preoperative detection of pancreatic insulinomas on multiphasic helical CT AJR. Am J Roentgenol 181 2003 775 780
105. H. Gouya, O. Vignaux, J. Augui CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas AJR Am J Roentgenol 181 2003 987 992
106. S. Bonekamp, C.P. Corona-Villalobos, I.R. Kamel Oncologic applications of diffusion-weighted MRI in the body J Magn ResI Imag 35 2012 257 279
107. Y. Wang, Z.E. Chen, V. Yaghmai Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics J Magn ResI Imag 33 2011 1071 1079
108. G. Kloppel, A. Couvelard, A. Perren ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification Neuroendocrinology 90 2009 162 166
109. I. Apostolova, S. Riethdorf, R. Buchert SPECT/CT stabilizes the interpretation of somatostatin receptor scintigraphy findings: a retrospective analysis of inter-rater agreement Ann Nucl Med 24 2010 477 483
110. D.L. Bushnell, R.P. Baum Standard imaging techniques for neuroendocrine tumors Endocrinol Metab Clin North Am 40 2011 153 162l
111. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol J Nucl Med 52 2011 697 704
112. 18F-FDG PET J Nucl Med 51 2010 704 712
113. 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours Nucl Med Commun 32 2011 91 97
114. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 Eur J Nucl Med Mol Imag 32 2005 724
115. 18F]fluorodihydroxyphenylalanine PET/CT for imagine neuroendocrine tumors Br J Surg 97 2010 691 697
116. 18F-DOPA PET/CT biodistribution consideration in 107 consecutve patients with neuroendocrine tumors Nucl Med Commun 33 2012 179 184
117. Y.C. Patel Somatostatin and its receptor family Front Neuroendocrinol 20 1999 157 198
118. J. Rubin, J. Ajani, W. Schirmer Octreotide acetate long-Acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome J Clin Oncol 17 1999 600 606
119. T. Nakamura, K. Kudoh, K. Takebe Octreotide decreased biliary and pancreatic exocrine function, and induces steatorrhea in healthy subjuects Intern Med 33 1994 593 596
120. S. Megalla, D. Holtzman, W.S. Aronow Predictors of cardiac hepatopathy in patients with right heart failure Med Sci Monitor 17 2011 CR537 CR541
121. 12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors Aliment Pharmacol Ther 27 2008 1110 1112
122. R. Kapoor, C. James, K. Hussain Advances in the diagnosis and management of hyperinsulinemic hypoglycemia Nat Clin Pract Endocrinol Metab 52 2009 101 112
123. J.G. Castillo, F. Filsoufi, D.H. Adams Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist Br J Anaesthesia 101 2008 618 626
124. W.C. Parris, J.A. Oates, J. Kambam Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome Can J Anaesth 35 1988 413 416
125. D.J. Vaughan, M.D. Brunner Anesthesia for patients with carcinoid syndrome Int Anesthesiol. Clin 35 1997 129 142
126. M.H. Kulke, E.K. Bergsland, J.C. Yao Glycemic control in patients with insulinoma treated with everolimus N Engl J Med 360 2009 195 197
127. S. Reddy, B. Clary Neuroendocrine liver metastases Surg Clin North Am 90 2010 853 861
128. G. Kerstrom, P. Hellman, O. Hessman Midgut carcinoid tumours: surgical treatment and prognosis Best Pract Res Clin Gastroenterol 19 2005 717 728
129. J.A. Chan, D.P. Ryan, C.S. Fuchs Phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET) ASCO Gastrointestinal Cancers Symposium Annual Meeting 2010 abstract 238
130. B. Wiedenmann, M. Pavel, T. Seufferlein The effect of telotristat etiprate on clinical and biochemical responses in patients with symptomatic carcinoid syndrome: preliminary results of an ongoing phase II, multicenter, open-label, serial-Ascending dose study J Clin Oncol 30 2012 abstract e14564
131. J.C. Yao, M.H. Shah, T. Ito Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523